Abstract:5555 Background: High grade serous ovarian cancer (HGSC) is a complex deadly disease. Due to the lack of symptoms at early stages, vast majority patients present at stage III/IV. Frontline chemotherapy and surgery is effective with nearly all patients experiencing a remission, though over 80% patients will recur in the first 1-2 years and ultimately die of the disease in the next few years. Approximately 20% will be long-term survivors, but no current clinical data can predict who may be a short- or long-term survivor. Clinical management, monitoring, and systemic treatment decisions could be optimally individualized to patients if able to better define the prognosis. The goal of this study is to employ artificial intelligence multi-omic machine learning models to predict survival outcomes. Methods: Clinical data and tumor specimens from University of Pittsburgh Center from 2010-2016 were analyzed. Patient data, whole exome sequencing (WES), whole transcriptome sequencing (WTS), drug response profile, and digital pathology profile were used as input feature sets for training the multi-omic machine learning (ML) models. Hypothesis-free training of the ML models was utilized to classify patient survival at 2yr and 5yr threshold. Model performance was estimated using AUROC (area under the receiver operating characteristic curve) metric, scores >0.5 having higher prediction potential. Validation of the prediction results of each ML model with top performing models meeting statistical significance threshold of α=0.01. Results: 160 HGSC model builds were completed. ML models achieved high prediction accuracy for both short-term (2y) and long-term (5y) patient cohorts, identifying 7 models with ≥ 0.7 AUROC model performance for 2yr OS threshold and 13 models with ≥ 0.7 AUROC model performance for 5yr OS threshold. Addition of multi-omic feature sets to clinical profile improved the model’s ability to predict OS for both short-term and long-term thresholds. Multi-omic feature set inputs led to superior prediction and improved performance over clinical profile information alone, and top performing multi-omic models predicted better than any feature set in isolation. Comparison of top features identified by 2y and 5y OS threshold models, we found that molecular features (WTS followed by WES feature sets) predominantly drove 2y cohort while digital pathology imaging features were the driver the 5y cohort top performing models. Conclusions: Current clinical data does not accurately predict prognosis. Utilizing multi-omic machine learning models, superior prediction of short- and long-term survivors was achieved. The specific drivers of the top performing models were different for the short- and long-term cohorts, identifying future research opportunities as well as development potential of a clinical decision tool.

Non-Small Cell Lung Cancer Survival Estimation Through multi-omic two-layer SVM: a Multi-Omics and Multi-Sources Integrative Model

Enhancing Non-Small Cell Lung Cancer Survival Prediction through Multi-Omics Integration Using Graph Attention Network

Integration of multi-omics data for survival prediction of lung adenocarcinoma

Multimodal Survival Ensemble Network: Integrating Genomic and Histopathological Insights for Enhanced Cancer Prognosis.

Integrative survival analysis of breast cancer with gene expression and DNA methylation data

Radiotranscriptomics of non-small cell lung carcinoma for assessing high-level clinical outcomes using a machine learning-derived multi-modal signature

Long-term cancer survival prediction using multimodal deep learning

Large-scale benchmark study of survival prediction methods using multi-omics data

Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer

Support Vector Machine Approaches for Tumor Classification and Survival Prediction in Cancer Patients: A Multi-Omics Data Analysis

Pancancer survival prediction using a deep learning architecture with multimodal representation and integration

Abstract 5395: Improving survival prediction using flexible late fusion machine learning framework for multi-omics data integration

A multimodal ensemble approach for clear cell renal cell carcinoma treatment outcome prediction

Strategies to integrate multi-omics data for patient survival prediction

Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers with Gene-Gene Interactions and Main Effects.

Predicting Deep Learning Based Multi-Omics Parallel Integration Survival Subtypes in Lung Cancer Using Reverse Phase Protein Array Data

Multimodal Learning for Non-small Cell Lung Cancer Prognosis

Using artificial intelligence-powered evidence-based molecular decision-making for improved outcomes in ovarian cancer.

DeepMOCCA: A pan-cancer prognostic model identifies personalized prognostic markers through graph attention and multi-omics data integration

Deep learning survival model on transcriptomes level in patients with non-small cell lung cancer.